FOR IMMEDIATE RELEASEBRADENTON, Fla. — October 1, 2026 — Trump Inc., an independent publication examining the Trump administration through business, economics and deal structure, has published “CHINA’S PLANES. TRUMP’S LEVERAGE.” The article examines how access to essential aviation supplies can become negotiating power.
The analysis follows Reuters reporting that the U.S. Commerce Department has slowed aircraft-parts export licensing to China while officials consider additional restrictions. Washington is seeking improved access to Chinese rare earths. The contemplated new rules remain proposals.
The article opens with a business principle:
“You can own the aircraft and still depend on somebody else to keep it flying.”
Trump Inc. examines the distinction between owning an expensive asset and having reliable access to the supplies needed to operate it. Its interpretation is that continued operation—not simply the aircraft’s purchase price—can become a valuable point of leverage.
The article also considers the cost of exercising that leverage. American suppliers could gain strategic importance while facing risks to sales, delivery confidence and future customer relationships. Buyers concerned about interruptions may seek alternative suppliers or stronger contractual assurances.
Rather than declaring a negotiating victory, the analysis identifies outcomes readers can use to assess the approach: dependable access to needed materials, predictable licensing, actual deliveries and the commercial costs borne by suppliers and customers.
The publication distinguishes Reuters’ reporting from its own economic interpretation and hypothetical examples. It does not characterize the proposed restrictions as enacted rules or claim that China’s fleet has been grounded.
Read the full article:
https://donaldtrumpinc.com/chinas-planes-trumps-leverage/
About Trump Inc.
Trump Inc. covers the business of the Trump administration through economics, markets, operations and deal structure. Its editorial approach examines what agreements deliver, who benefits, who bears the risks and whether promised results materialize.
Publication information:
https://donaldtrumpinc.com
Reporting source: Reuters, October 1, 2026.